Decitabine for treatment of myelodysplastic syndrome in an elderly patient and review of literature

Findings in epigenetic changes in meylodysplastic syndromes(MDS) and the development of demethylating drugs provide a new approach to the treatment of MDS.We used standard-dose decitabine for treatment of MDS in an elderly patient with an International Prostate Symptom Score(IPSS) of moderate risk group 2,and achieved a complete response in the first course.We report our experience with this case and review the relevant literatures.